R & D daily / Sanofi long acting insulin approved for extended indications

Innovative therapy targeting FGF receptor Incyte cholangiocarcinoma has been qualified for priority review; Sanofi long-acting insulin has been approved to expand the indications for the benefit of type 1 diabetic patients; anticoagulation therapy for children! Bayer submits xarlto application; Sanofi long-acting insulin is approved for extended indications We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel Today, Incyte announced that the US FDA has accepted the application for a new drug of its FGFR1 / 2 / 3 inhibitor pemigatinib for the treatment of locally advanced or metastatic intrahepatic cholangiocarcinoma patients carrying FGFR2 gene fusion or rearrangement The FDA also granted the application a priority review qualification and is expected to respond by May 30 next year Recently, the U.S FDA approved the expansion of the application of Sanofi's long-acting insulin glargine injection toujeo for the treatment of children and adolescents with type 1 diabetes mellitus aged 6 and above Based on the results of the edition junior trial published earlier this month, the European Drug Administration Commission on human drugs also recommended approval of the extended indications Bayer recently announced that it has submitted an application to the European drug administration to expand the indications of the anticoagulant xarloto (rivaroxaban) for children under the age of 17 who have been diagnosed with VTE, including CVST.